Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia

NCT00811733 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00811733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00811733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
March 1, 2009
Completion date
February 1, 2014
Enrollment
37 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

waldenstrom macroglobulinaemia